Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥1,522 JPY
Change Today +169.00 / 12.49%
Volume 7.3M
As of 1:00 AM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

sumitomo dainippon pharma co (4506) Snapshot

Open
¥1,425
Previous Close
¥1,353
Day High
¥1,531
Day Low
¥1,425
52 Week High
03/11/14 - ¥1,892
52 Week Low
05/27/14 - ¥1,095
Market Cap
605.6B
Average Volume 10 Days
1.6M
EPS TTM
¥50.08
Shares Outstanding
397.9M
EX-Date
03/27/15
P/E TM
30.4x
Dividend
¥18.00
Dividend Yield
1.18%
Current Stock Chart for SUMITOMO DAINIPPON PHARMA CO (4506)

Related News

No related news articles were found.

sumitomo dainippon pharma co (4506) Related Businessweek News

No Related Businessweek News Found

sumitomo dainippon pharma co (4506) Details

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients, food additives, veterinary medicines, diagnostics, and others in Japan, China, North America, and other regions. The company offers pharmaceutical products, such as therapeutic agents for hypertension, angina pectoris, arrhythmia, Parkinson’s disease, systemic fungal infections, and hepatocellular carcinoma; atypical antipsychotics; antidepressants; rapid-acting insulin secretagogues; vasodilators; and biguanide oral hypoglycemic drugs. It also provides products for therapeutic indications, such as Anderson-Fabry disease, anti-hypertension, gastroprokines, carbapenem antibiotics, sedative hypnotics, short-acting and long-acting beta-agonist, inhaled corticosteroid, corticosteroid nasal spray, and serotonin-agonist antianxiety drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, seasonings, and sweeteners; and chemical product materials, such as cosmetic and coating materials, active pharmaceutical ingredients, and electronic chemicals. Further, it offers veterinary medicines for companion animals, including dogs and cats; and farm animals, such as cattle, swine, horses, and cultured fish. Additionally, the company develops point-of-care testing diagnostic products for infectious diseases and acute myocardial infarctions; in-vitro diagnostics for bone and calcium metabolism, and central nervous system disorders; research materials that facilitate research related to medical care; and BBI608 and BBI503 anticancer drug candidates. It has a joint development agreement with Healios K.K. to develop iPS cell-derived retinal pigment epithelial cells for the treatment of age-related macular degeneration and other eye diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. The company was founded in 1897 and is headquartered in Osaka, Japan.

7,015 Employees
Last Reported Date: 06/19/14
Founded in 1897

sumitomo dainippon pharma co (4506) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

sumitomo dainippon pharma co (4506) Key Developments

DKSH Signs Agreement with Sumitomo Dainippon Pharma Co., Ltd. for Antipsychotic Drug

DKSH reached an agreement with Sumitomo Dainippon Pharma Co., Ltd. for the introduction and launch of Sumitomo's lurasidone hydrochloride, an atypical antipsychotic drug, in Thailand, Singapore and Hong Kong. DKSH Business Unit Healthcare will provide marketing, sales and regulatory services as well as distribution and logistics for lurasidone hydrochloride (generic name, "lurasidone") in Thailand, Singapore and Hong Kong.

Sumitomo Dainippon Enters into Agreement with DKSH to Market and Distribute Its Atypical Antipsychotic Treatment Latuda in Thailand, Singapore, and Hong Kong

Sumitomo Dainippon entered into an agreement with DKSH to market and distribute its atypical antipsychotic treatment Latuda (lurasidone hydrochloride) in Thailand, Singapore, and Hong Kong. DKSH submitted a new drug approval application for Latuda targeting schizophrenia in Thailand in November, as well as in Hong Kong in December. In addition, DKSH plans to submit an application to the Singapore authorities this month.

Sumitomo Dainippon Pharma Co., Ltd. Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014 ; Revises Earnings Guidance for the Fiscal Year 2014 ; Provides Year End Dividend Guidance for the Year Ending March 31, 2015

Sumitomo Dainippon Pharma Co., Ltd. reported consolidated earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported net sales of JPY 100.8 billion compared to JPY 103.1 billion a year ago. Operating income was JPY 10.9 billion compared to JPY 17.2 billion a year ago. Ordinary income was JPY 9.8 billion compared to JPY 16.9 billion a year ago. Net income was JPY 7.2 billion compared to JPY 10.5 billion a year ago. Income before income taxes and minority interests was JPY 12.2 billion compared to JPY 16.8 billion a year ago. For the nine months, the company reported net sales of JPY 279.1 billion compared to JPY 284.5 billion a year ago. Operating income was JPY 22.8 billion compared to JPY 34.7 billion a year ago. Ordinary income was JPY 22.5 billion compared to JPY 34.3 billion a year ago. Net income was JPY 19.0 billion compared to JPY 19.2 billion a year ago. EBITDA was JPY 37.3 billion compared to JPY 55.2 billion a year ago. Net cash provided by operating activities was JPY 26.9 billion compared to JPY 35.4 billion a year ago. Return on equity was 4.5% compared to 5.1% a year ago. Earnings per share were JPY 47.81 compared to JPY 48.22 a year ago. Capital expenditures were JPY 8.5 billion compared to JPY 11.3 billion a year ago. Income before income taxes and minority interests was JPY 34.3 billion compared to JPY 31.8 billion a year ago. The company revised earnings guidance for the fiscal year 2014. For the year, the company expects net sales of JPY 371.0 billion, operating income of JPY 20.0 billion, ordinary income of JPY 20.0 billion, net income of JPY 12.5 billion and EBITDA of JPY 39.5 billion compared to previous guidance of net sales of JPY 366.0 billion, operating income of JPY 20.0 billion, ordinary income of JPY 19.5 billion, net income of JPY 14.0 billion and EBITDA of JPY 39.0 billion. The company expects capital expenditures of JPY 12.0 billion and depreciation and amortization on property, plant and equipment of JPY 7.3 billion, on intangible assets of JPY 4.2 billion and on goodwill of JPY 5.5 billion. The company expects earnings per share of JPY 31.46 compared to previous guidance earnings per share of JPY 35.24. The company forecasts year dividend of JPY 9.00 per share compared to JPY 9.00 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4506:JP ¥1,522.00 JPY +169.00

4506 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albany Molecular Research Inc $17.45 USD -0.32
FUJIFILM Holdings Corp ¥4,107 JPY +31.50
GlaxoSmithKline Consumer Nigeria PLC 40.00 NGN 0.00
Teva Pharmaceutical Industries Ltd $56.40 USD -0.11
Vanda Pharmaceuticals Inc $10.47 USD -0.24
View Industry Companies
 

Industry Analysis

4506

Industry Average

Valuation 4506 Industry Range
Price/Earnings 30.3x
Price/Sales 1.6x
Price/Book 1.3x
Price/Cash Flow 17.6x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUMITOMO DAINIPPON PHARMA CO, please visit www.ds-pharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.